The disease can cause it to become harder and harder to breathe - and it's key you keep an eye out for symptoms ...
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
5d
GlobalData on MSNBoehringer seeks approval of lung disease drug after second Phase III successBoehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 ...
The "Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of the Cough in ...
If you have a cough and are putting it down to 'just you' or 'that illness' you've had for weeks, you should see a GP, a ...
The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...
Long-term exposure to toxic air pollutants, particularly carcinogens like benzene, formaldehyde, and polycyclic aromatic ...
The following is a summary of “Development of the pulmonary fibrosis, pulmonary vascular resistance, six minute walk distance, B-type natriuretic peptide, age (PVD-B65) risk score for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results